Licensing or transferring patents, software and know-how turns research investment into revenue and partnerships without giving up ownership of the underlying technology. It is how a business with strong IP but limited reach can put that technology into more markets, more products and more hands than it could ever serve alone. It also carries real risk: poorly defined scope, weak treatment of improvements, and missing confidentiality terms can quietly erode the value of the very technology you set out to monetise.
Technology licensing is more demanding to get right than licensing a finished product, because what is being licensed is often intangible, evolving and hard to put back in the box once it has been shared. The agreement has to anticipate how the technology will be used, improved and protected over the life of the deal.
Scope sits at the centre. The licence has to define the field of use, the territory, whether it is exclusive or non-exclusive, and whether the licensee can sublicense. From there come the commercial terms: the royalty model, minimum commitments, reporting and audit rights, and the milestones that trigger payments. For technology specifically, two areas need particular care. The first is improvements and derivatives: when either side develops the technology further during the licence, the agreement must say who owns those improvements and who may use them, or the parties will end up in a dispute precisely because the deal succeeded. The second is confidentiality and protection of know-how, where reverse-engineering restrictions and security obligations matter as much as the formal grant, because much of the value in technology lives in the know-how around the patent rather than in the patent claims alone.
Not every deal is a licence. Sometimes the right structure is an outright assignment, transferring the patent or technology to the other party, and sometimes it is a hybrid, with ownership moving but a licence-back retained, or staged transfers tied to payment. Choosing between licensing and transfer is a commercial and tax decision as much as a legal one, and it should be made deliberately rather than by default.
Patent and technology licensing sits in the Commercialize stage of our 360 method and is part of our commercial contracts and transactions work. It builds on patent protection and patent strategy upstream, because a licence is only as strong as the rights behind it, and the income it produces can feed the innovation income deduction on the tax side, which is why we model the licensing and tax positions together. The background sits in the Knowledge Base on structuring licensing agreements, and the drafting runs through our Contract Studio and Clause Library technology.
We choose the right structure, value and protect the technology, draft and negotiate the terms, and coordinate the licensing position with patent strategy and tax so the deal captures full value rather than leaking it through loose drafting.
It depends on your goals. Licensing keeps ownership and creates a recurring revenue stream while letting others commercialise the technology; a sale realises value now but gives up future upside. Tax treatment and your longer-term strategy both feed into the choice, which is why we look at them together.
Whoever the contract specifies. This is one of the most contested points in technology licensing, because both sides may invest in developing the technology further. A well-drafted licence settles ownership and use of improvements before they are made.
Commonly as a percentage of net sales, sometimes with minimum annual commitments, upfront fees or milestone payments. Audit and reporting rights back the royalty up so you can verify what is owed. The right model depends on the technology and the market.
It can. Income from qualifying IP may fall within the Belgian innovation income deduction, which is why we coordinate licensing with the tax position rather than treating them as separate exercises.
%402x.svg){kind=icon}
%402x.svg){kind=icon}
%402x.svg){kind=small}